Streetbeat News

Products Services

SABS

SAB Biotherapeutics announced positive safety and pharmacologic data from a GLP toxicology study for SAB-142, a Type 1 Diabetes immunotherapy. The study met its primary objective, and the company plans to submit an IND application and initiate a Phase 1 trial in the next few months.

Portfolio Pulse from Vandana Singh

June 21, 2023 | 12:00 pm

SABS

SAB Biotherapeutics announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a potential treatment for autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:59 am

AAPL

Apple's iOS 17 introduces an expanded Visual Look Up feature that can recognize common symbols on car dashboards, providing users with valuable information about warning lights and other icons. The update is currently in developer beta testing, with a public beta set for July and an official release in September.

Portfolio Pulse from Sudhanshu Singh

June 21, 2023 | 11:55 am

VZ

Samsung's Galaxy S23 Ultra is now available with up to $1,000 off and a free 4K Samsung TV on Verizon Communications Inc. (NYSE:VZ) for the 256GB version. The 512GB version is available at a higher monthly payment. Subscribers must have an unlimited data plan with Verizon to be eligible for this offer.

Portfolio Pulse from Rounak Jain

June 21, 2023 | 11:39 am

COIN

Coinbase shares are trading higher as Bitcoin's price increases following BlackRock's application for a Bitcoin ETF.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 11:35 am

CMMB

Chemomab Therapeutics reported positive data from the secondary analysis of its Phase 2a liver fibrosis trial assessing CM-101, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:20 am

EXAS

Exact Sciences has partnered with two renowned healthcare organizations to advance innovative cancer technologies and approaches. The collaboration aims to improve cancer detection, diagnosis, and treatment.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:19 am

RIVN

Rivian Automotive (NASDAQ:RIVN) plans to unveil its R2 SUV in early 2024, with a price range of $40,000 to $60,000, targeting a broader market segment. The R2 will maintain Rivian's adventure aesthetic while showcasing key trade-offs and investments.

Portfolio Pulse from Anan Ashraf

June 21, 2023 | 11:19 am

UBX

Unity Biotechnology announced the design of its Phase 2B ASPIRE clinical trial for UBX1325 (Foselutoclax) to be conducted head-to-head against Aflibercept in previously treated patients with active diabetic macular edema. The first patient is expected to be dosed in Q4 of 2023.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 11:17 am